CoChat

CAR T cells in solid tumors: challenges and opportunities

Open access

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Abstract

BACKGROUND: CARs are simulated receptors containing an extracellular single-chain variable fragment (scFv), a transmembrane domain, as well as an intracellular region of immunoreceptor tyrosine-based activation motifs (ITAMs) in association with a co-stimulatory signal. MAIN BODY: Chimeric antigen receptor (CAR) T cells are genetically engineered T cells to express a receptor for the recognition of the particular surface marker that has given rise to advances in the treatment of blood disorders. The CAR T cells obtain supra-physiological properties and conduct as "living drugs" presenting both immediate and steady effects after expression in T cells surface. But, their efficacy in solid tumor treatment has not yet been supported. The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and exhaustion, and as a result of the combined use of CARs and checkpoint blockade, as well as the suppression of other inhibitor factors in the microenvironment, very promising results were obtained from the reduction of T cell exhaustion. CONCLUSION: Nowadays, identifying and defeating the mechanisms associated with CAR T cell dysfunction is crucial to establish CAR T cells that can proliferate and lyse tumor cells severely. In this review, we discuss the CAR signaling and efficacy T in solid tumors and evaluate the most significant barriers in this process and describe the most novel therapeutic methods aiming to the acquirement of the promising therapeutic outcome in non-hematologic malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-020-02128-1

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CAR T cell engineering. The design of the CAR T cell has evolved by combining existing immune cell components to facilitate direct targeting of tumor antigens. scFv of CAR-induced light and heavy chains of the antibody variable region, whereas the CAR amplitude CD3ζ has been derived from the intracellular signaling domains of the TCR
Fig. 1 CAR T cell engineering. The design of the CAR T cell has evolved by combining existing immune cell components to facilitate direct targeting of tumor antigens. scFv of CAR-induced light and heavy chains of the antibody variable region, whereas the CAR amplitude CD3ζ has been derived from the intracellular signaling domains of the TCRCC BY · PubMed Central
Fig. 2 CAR T cell engineering. The specificity of T cells against tumor cells is mediated by CAR proteins. CAR is a combination of extracellular proteins and is usually derived from antibodies and intracellular signaling modules derived from T cell signaling proteins. First-generation CARs have been composed of CD3ζ, while adding a costimulatory endodomain including CD28 or 4BB to CD3ζ has led to the creation of second-generation CARs. Third-generation cars include two costimulatory domains fused to CD3ζ. VH, variable heavy chain; VL, variable light chain; scFv, single-chain variable fragment. Generation of CAR T cells leads to the initiation of different signaling pathways which caused cell survival, proliferation, and cytokine production
Fig. 2 CAR T cell engineering. The specificity of T cells against tumor cells is mediated by CAR proteins. CAR is a combination of extracellular proteins and is usually derived from antibodies and intracellular signaling modules derived from T cell signaling proteins. First-generation CARs have been composed of CD3ζ, while adding a costimulatory endodomain including CD28 or 4BB to CD3ζ has led to the creation of second-generation CARs. Third-generation cars include two costimulatory domains fused to CD3ζ. VH, variable heavy chain; VL, variable light chain; scFv, single-chain variable fragment. Generation of CAR T cells leads to the initiation of different signaling pathways which caused cell survival, proliferation, and cytokine productionCC BY · PubMed Central
Fig. 3 T cell-mediated antitumor effects by chimeric antigen receptors. CAR-modified T cells can detect tumor cells by CAR binding to TAA independent of the TCR-MHC/peptide interaction
Fig. 3 T cell-mediated antitumor effects by chimeric antigen receptors. CAR-modified T cells can detect tumor cells by CAR binding to TAA independent of the TCR-MHC/peptide interactionCC BY · PubMed Central
Fig. 4 T cell-mediated antitumor effects by chimeric antigen receptors. T cells are activated and can kill tumor cells by secreting granzymes and perforin, as well as the expression of TRAIL and FasL. Moreover, immune cells that invade the tumor can be activated by secreting various cytokines
Fig. 4 T cell-mediated antitumor effects by chimeric antigen receptors. T cells are activated and can kill tumor cells by secreting granzymes and perforin, as well as the expression of TRAIL and FasL. Moreover, immune cells that invade the tumor can be activated by secreting various cytokinesCC BY · PubMed Central
Fig. 5 Isolation of CAR T cells and its interaction with tumor-associated antigens (TAA) in solid tumors. T cells are collected from patients’ peripheral blood via leukophores and are designed to express chimeric antigen receptors to tumor-specific antigens. These cells proliferate before being re-injected. After injection, autologous CAR-engineered T cells detect TAA and binds to its corresponding ligand, leading to the secretion of cytokines and the interaction of some apoptosis-related ligands, which ultimately leads to the destruction of tumor cells
Fig. 5 Isolation of CAR T cells and its interaction with tumor-associated antigens (TAA) in solid tumors. T cells are collected from patients’ peripheral blood via leukophores and are designed to express chimeric antigen receptors to tumor-specific antigens. These cells proliferate before being re-injected. After injection, autologous CAR-engineered T cells detect TAA and binds to its corresponding ligand, leading to the secretion of cytokines and the interaction of some apoptosis-related ligands, which ultimately leads to the destruction of tumor cellsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 150 references

Cited by

See all 617

Metadata

Authors
Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., Izadi, S., Hassanzadeh, A., Shirafkan, N., Tahmasebi, S., & Khiavi, F. M.
Affiliations
  • Tabriz University of Medical Sciences (IR)
  • Russian Academy of Sciences (RU)
  • Saveetha University (IN)
  • Sechenov University (RU)
  • Industrial University of Tyumen (RU)
  • German Cancer Research Center (DE)
  • University of South Florida (US)
  • Pasteur Institute of Iran (IR)
Corresponding author
  • Motavalli, Roza
  • Khiavi, Farhad Motavalli
Venue
Stem Cell Research & Therapy
Published
2021-01-25
Volume
12
Issue
1
Pages
81-81
ISSN
1757-6512 (ISSN-L)
OpenAlex
W3122724341
Cited by
582
References
149
Citations by year
2026: 63 · 2025: 105 · 2024: 120 · 2023: 133 · 2022: 121 · 2021: 39
FWCI
12.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor T cells, solid tumors, chimeric antigen receptor, tumor microenvironment, T cell exhaustion, immune checkpoint blockade, CAR signaling, T cell migration, tumor recognition, non-hematologic malignancies, T cell survival
MeSH terms
Receptors, Chimeric Antigen, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAR T cells in solid tumors: challenges and opportunities. https://app.cochat.ai/papers/10.1186/s13287-020-02128-1
The paper
Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., Izadi, S., Hassanzadeh, A., Shirafkan, N., Tahmasebi, S., & Khiavi, F. M. (2021). CAR T cells in solid tumors: challenges and opportunities. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-020-02128-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.